东北制药：DCTY0801注射液药物临床试验获批

Core Viewpoint - Northeast Pharmaceutical (000597) announced the approval of a clinical trial for its CAR-T cell product DCTY0801 injection, targeting EGFRvIII positive recurrent or progressive high-grade glioma [1] Company Summary - The company’s subsidiary, Beijing Dingcheng Peptide Source Biotechnology Co., Ltd., received the clinical trial approval from the National Medical Products Administration [1] - DCTY0801 injection is specifically designed to target the EGFRvIII mutation antigen [1]